202-765-1429     pharmd@gmail.com

The right drug. The first time.

It is a given in medicine that individuals vary in their responses to drug therapy. The unique differences in genetic makeup among individuals play an important role in the pharmacokinetic and pharmacodynamic variabilities in the drug response.

As a core element of precision medicine, pharmacogenomics (PGX), has the potential to identify drug therapy responders and non-responders and subsequently guide the creation of individualized treatment plan and dose optimization with the goal of maximizing the effectiveness of medications and minimize toxicities in individual patients.

Currently, over 350 medications contain pharmacogenomic information in their Food & Drug Administration (FDA) approved labels and package inserts.


Ineffective drug therapies often times result in hospitalizations and readmissions, adverse drug events, and increased mortality, thereby negatively impact the clinical outcomes of affected patients and thus, placing a significant burden on public health systems.


Having the patient’s genetic information prior to prescribing plays is important in the identification and prevention of drug-gene interactions (DGIs) or complex drug-drug-gene interactions (DDGI)s, which occurs due to the superimposition of drug-drug interactions (DDIs) on drug-gene interactions DGIs, especially in high-risk medically complex patients on multiple concomitant medications. This process ultimately guided the prospective selection of appropriate and personalized drug therapy for patients.3

What are the Benefits of the Pharmacogenomics Test?

• Optimize drug effectiveness

• Mitigate medication-related risks.

• Improve medication adherence

Which patients benefit from the Pharmacogenomics Test?


Pharmacogenomics Consults

Our pharmacists deploy evidence-based pharmacogenomics information in our pre and post-test consultations to physicians and patients. We analyze and distill complex pharmacogenomics information and create a personalized, comprehensive, easy-to-read and actionable report for prescribers to guide the selection of the therapeutic and cost-effective treatment pathway for patients. And we also engage and empower your patients to achieve the best possible outcomes.


Who we serve

PharmD Live is well-poised to set benchmarks for innovation and excellence within the healthcare ecosystem. We aim to create mutually beneficial relationships to maximize the delivery of value-based solutions for these organizations we serve by engaging and empowering your patients to achieve the best possible outcomes.

  • Managed Care Organizations/Health Plans

  • Self Insured Employers

  • Hospitals and Health Systems

  • Physician Practices

  • Pharmaceutical companies


Why use our pharmacists?

Our pharmacists are uniquely positioned to apply their advanced training to combine PGX information pertaining to a drug with their to provide well-informed, individualized treatment input.

Given our expertise in pharmacogenomics and extensive knowledge of drug pharmacology, drug-drug interactions, therapeutic dosage understanding, informatics, and patient care, PharmD Live pharmacists are best equipped to conduct pre- and post-genetic test consultations with physicians and patients and make drug therapy recommendations based on the genetic profile in order to achieve the desired treatment goal and minimize adverse drug reactions in patients, which is not only instrumental in decreasing morbidity, mortality, and healthcare costs, but also aids more accurate diagnosis and compliance with medications.


[1] Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352(21):2211–2221. doi: 10.1056/NEJMra032424

[2] Spear BB, Heath-Chiozzi M & Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001;7(5):201–204. PMID: 11325631

3. Hocum BT, White Jr JR, Heck JW, et al. Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. Am J Health Syst Pharm. 2016;73(2):61e67. 3. Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4): 533e544.

4. FDA